BMC psychiatry · 2014
Monitoring candidate gene expression variations before, during and after a first major depressive episode in a 51-year-old man.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Belzeaux Raoul, Azorin Jean-Michel, Ibrahim El Chérif
Аннотация
BACKGROUND: Although psychiatric disorders are frequently characterized by clinical heterogeneity, high recurrence, and unpredictable prognosis, studies of mRNA expression variations in blood cells from psychiatric patients constitute a promising avenue to establish clinical biomarkers. We report here, to our knowledge, the first genetic monitoring of a major depressive episode (MDE).
CASE PRESENTATION: The subject is a 51-year-old male, who was healthy at baseline and whose blood mRNA was monitored over 67 weeks for expression variations of 9 candidate genes. At week 20 the subject experienced a mild to moderate unexpected MDE, and oral antidepressant treatment was initiated at week 29. At week 36, the patient recovered from his MDE. After 6 months, antidepressant treatment was discontinued and the subject remained free of depressive symptoms. Genetic monitoring revealed that mRNA expression of SLC6A4/5HTT increased with the emergence of a depressive state, which later returned to basal levels after antidepressant treatment and during MDE recovery. PDLIM5, S100A10 and TNF mRNA showed also an interesting pattern of expression with regards to MDE evolution.
CONCLUSION: This case demonstrated the applicability of peripheral mRNA expression as a way to monitor the natural history of MDE.
CASE PRESENTATION: The subject is a 51-year-old male, who was healthy at baseline and whose blood mRNA was monitored over 67 weeks for expression variations of 9 candidate genes. At week 20 the subject experienced a mild to moderate unexpected MDE, and oral antidepressant treatment was initiated at week 29. At week 36, the patient recovered from his MDE. After 6 months, antidepressant treatment was discontinued and the subject remained free of depressive symptoms. Genetic monitoring revealed that mRNA expression of SLC6A4/5HTT increased with the emergence of a depressive state, which later returned to basal levels after antidepressant treatment and during MDE recovery. PDLIM5, S100A10 and TNF mRNA showed also an interesting pattern of expression with regards to MDE evolution.
CONCLUSION: This case demonstrated the applicability of peripheral mRNA expression as a way to monitor the natural history of MDE.
Предметные рубрики MeSH
Adaptor Proteins, Signal TransducingAnnexin A2Antidepressive AgentsMajor Depressive DisorderGene ExpressionGenetic Association StudiesGenetic MarkersGenetic VariationHumansLIM Domain ProteinsMaleMiddle AgedMonitoring, PhysiologicRNA, MessengerS100 ProteinsSerotonin Plasma Membrane Transport ProteinsSeverity of Illness IndexTumor Necrosis Factor-alphaS100 Calcium Binding Protein A10